DYN · Dyne Therapeutics Inc
United States · RS rating 16 · As of 2026-10-14
| Price | 15.04 USD |
|---|---|
| 1-day change | -1.7% |
| RS rating (overall / 1M / 3M / 12M) | 16 / 15 / 10 / 56 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 29 / 19 / 25 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +0.0% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +43.8% |
| Market cap (USD) | $3.1B |